Skip to main content

Table 1 Clinical and Molecular Characteristics of Included Patients

From: Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis

  TKI alone TKI + RT  
Characteristic (n = 29) % (n = 49) % p Value
Age (years)      0.639
 Median 59   59   
 Range 32–74   35–83   
 < 65 21 72.4 33 67.3  
 ≥65 8 27.6 16 32.7  
Gender      0.729
 Male 13 44.8 20 40.8  
 Female 16 55.2 29 59.2  
Smoking history      0.729
 Never or light 16 55.2 29 59.2  
 Heavy 13 44.8 20 40.8  
EGFR mutation      0.323
 Del19 9 31.0 22 44.9  
 L858r 18 62.0 26 53.1  
 Other 2 7.0 1 2.0  
BM no. at time of diagnosis      0.292
 ≤3 16 55.2 21 42.9  
 >3 13 44.8 28 57.1  
Extracranial metastases      0.454
 Yes 24 82.8 37 75.5  
 No 5 17.2 12 24.5  
Intracranial Symptoms      0.012
 Without 22 75.9 23 46.9  
 With 7 24.1 26 53.1  
Lung-mol GPA classification      0.339
 0–1 1 3.5 2 4.1  
 1.5–2 9 31.0 12 24.5  
 2.5–3 12 41.4 22 44.9  
 3.5–4 7 24.1 13 26.5  
Primary tumor location      0.128
 Left Lung 17 58.6 20 40.8  
 Right Lung 12 41.4 29 59.2  
KPS score(%)      0.801
 <80 6 20.7 9 18.4  
 ≥80 23 79.3 40 81.6  
\